A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non‐Small Cell Lung Cancer

(2018) Manmeet S. Ahluwalia et al.   ONCOLOGIST

Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance

(2018) Carina Heydt et al.   Oncotarget

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

(2018) Yi-Long Wu et al.   JOURNAL OF CLINICAL ONCOLOGY

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Thanyanan Reungwetwattana et al.   JOURNAL OF CLINICAL ONCOLOGY

Stan: A Probabilistic Programming Language

(2017) Bob Carpenter et al.   Journal of Statistical Software

Durable response to osimertinib in EGFR mutated T790M wildtype non-small cell lung cancer with leptomeningeal metastases: A case report

(2017) Anna Chalmers et al.   LUNG CANCER

Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation

(2017) Taro Koba et al.   MEDICINE

Revisiting the Logan plot to account for non-negligible blood volume in brain tissue

(2017) Martin Schain et al.   EJNMMI Research

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

(2016) P. Ballard et al.   CLINICAL CANCER RESEARCH

Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

(2016) Hermann Reichegger et al.   Oncology Research and Treatment

Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates

(2015) Magnus Schou et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers

(2015) Deepa Rangachari et al.   LUNG CANCER

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

(2014) M. Raymond V. Finlay et al.   JOURNAL OF MEDICINAL CHEMISTRY

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

The Management of Brain Metastases in Non-Small Cell Lung Cancer

(2014) Scott Owen et al.   Frontiers in Oncology

Modeling of PET data in CNS drug discovery and development

(2013) Katarina Varnäs et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation

(2011) Oscar Arrieta et al.   Radiation Oncology

Implications of key trials in advanced nonsmall cell lung cancer

(2010) Philip D. Bonomi   CANCER

Development of Central Nervous System Metastases in Patients with Advanced Non-Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

(2010) S. Heon et al.   CLINICAL CANCER RESEARCH

Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT

(2009) Andrea Varrone et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

[18F]Flumazenil binding to central benzodiazepine receptor studies by PET

(2008) Ikuo Odano et al.   NEUROIMAGE